We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of New Anti-Infective Drugs for the Treatment of Genital Infections Due to Herpes Simplex Virus.
- Authors
Corey, Lawrence; McCutchan, J. Allen; Ronald, Allan R.; Handsfield, H. Hunter
- Abstract
This guideline addresses clinical trials of new therapies for genital infections due to herpes simplex virus (HSV). Of the two types of virus, HSV-2 is the more common pathogen. Both HSV-1 and HSV-2 become latent in sacral nerve root ganglia and intermittently reactivate. Patients who have frequent recurrences (more than four per year) may be candidates for long-term suppressive therapy. In both first-episode and recurrent genital HSV infections, lesions should be cultured for HSV. Testing for human immunodeficiency virus is encouraged but not required. Serum antibodies to HSV-1 and HSV-2 should be quantitated at enrollment and 3–5 weeks thereafter. Randomized, double-blind, active-control comparative studies are generally recommended. Placebo-controlled trials may be appropriate for recurrent genital herpes or for suppression of recurrences. Final evaluation should generally take place 10–15 days after the completion of therapy.
- Publication
Clinical Infectious Diseases, 1992, Vol 15, Issue Supplement_1, pS99
- ISSN
1058-4838
- Publication type
Article